Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases

Reuters01-16

Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases

Vor Biopharma Inc. presented updates on its lead autoimmune programs targeting B cell-driven diseases through BAFF/APRIL inhibition with telitacicept, a selective BAFF/APRIL inhibitor. The company highlighted ongoing and upcoming global Phase 3 clinical trials in myasthenia gravis, with topline data expected in the first half of 2027, and in Sjögren's disease, which is set to begin in the first half of 2026. Telitacicept has shown clinical validation across more than eight autoimmune indications in China and has been administered to tens of thousands of patients with a manageable safety and tolerability profile. Adverse events reported in clinical trials were primarily mild to moderate, including upper respiratory tract infection, injection site reaction, urinary tract infection, cough, and diarrhea. The company reported a strong cash position of $450 million as of December 2025, expected to fund operations into mid-2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603336589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603336589","market":"fut","top_or_hot":-1,"title":"Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VOR\">Vor Biopharma Inc.</a> presented updates on its lead autoimmune programs targeting B cell-driven diseases through BAFF/APRIL inhibition with telitacicept, a selective BAFF/APRIL inhibitor. The company highlighted ongoing and upcoming global Phase 3 clinical trials in myasthenia gravis, with topline data expected in the first half of 2027, and in Sjögren's disease, which is set to begin in the first half of 2026. Telitacicept has shown clinical validation across more than eight autoimmune indications in China and has been administered to tens of thousands of patients with a manageable safety and tolerability profile. Adverse events reported in clinical trials were primarily mild to moderate, including upper respiratory tract infection, injection site reaction, urinary tract infection, cough, and diarrhea. The company reported a strong cash position of $450 million as of December 2025, expected to fund operations into mid-2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-16 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VOR\">Vor Biopharma Inc.</a> presented updates on its lead autoimmune programs targeting B cell-driven diseases through BAFF/APRIL inhibition with telitacicept, a selective BAFF/APRIL inhibitor. The company highlighted ongoing and upcoming global Phase 3 clinical trials in myasthenia gravis, with topline data expected in the first half of 2027, and in Sjögren's disease, which is set to begin in the first half of 2026. Telitacicept has shown clinical validation across more than eight autoimmune indications in China and has been administered to tens of thousands of patients with a manageable safety and tolerability profile. Adverse events reported in clinical trials were primarily mild to moderate, including upper respiratory tract infection, injection site reaction, urinary tract infection, cough, and diarrhea. The company reported a strong cash position of $450 million as of December 2025, expected to fund operations into mid-2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VOR","symbol_name":"Vor Biopharma Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL3bM2n3:1","article_id":"2603336589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603336589","pubTimestamp":1768507590,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vor Biopharma Inc. presented updates on its lead autoimmune programs targeting B cell-driven diseases through BAFF/APRIL inhibition with telitacicept, a selective BAFF/APRIL inhibitor. The company highlighted ongoing and upcoming global Phase 3 clinical trials in myasthenia gravis, with topline data expected in the first half of 2027, and in Sjgren's disease, which is set to begin in the first half of 2026. Telitacicept has shown clinical validation across more than eight autoimmune indications in China and has been administered to tens of thousands of patients with a manageable safety and tolerability profile. Adverse events reported in clinical trials were primarily mild to moderate, including upper respiratory tract infection, injection site reaction, urinary tract infection, cough, and diarrhea. The company reported a strong cash position of $450 million as of December 2025, expected to fund operations into mid-2028. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VOR":"Vor Biopharma Inc.","BK4139":"生物科技"},"translate_title":"Vor Biopharma公布针对B细胞驱动的自身免疫性疾病的Telitacicept数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOR":0.9},"content_text":"Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases\n    \n\nVor Biopharma Inc. presented updates on its lead autoimmune programs targeting B cell-driven diseases through BAFF/APRIL inhibition with telitacicept, a selective BAFF/APRIL inhibitor. The company highlighted ongoing and upcoming global Phase 3 clinical trials in myasthenia gravis, with topline data expected in the first half of 2027, and in Sjögren's disease, which is set to begin in the first half of 2026. Telitacicept has shown clinical validation across more than eight autoimmune indications in China and has been administered to tens of thousands of patients with a manageable safety and tolerability profile. Adverse events reported in clinical trials were primarily mild to moderate, including upper respiratory tract infection, injection site reaction, urinary tract infection, cough, and diarrhea. The company reported a strong cash position of $450 million as of December 2025, expected to fund operations into mid-2028. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603336589","isCrawlerRequest":true}